GENE Genetic Technologies Limited: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Genetic Technologies (GENE) leads in preventive diagnostics, offering unique GeneType tests for the early detection of diabetes and oncology. The business relies on a network of advanced laboratories in the US and Australia where genetic data is analyzed. This chart of share prices demonstrates an EV/EBITDA multiple of . Meanwhile, the company strictly adheres to biomaterial disposal regulations and maintains basic office environmental standards.

Genetic Technologies Ltd - GENE Total Company Value to Operating Income Before Depreciation Ratio (period 07/04/2022 - 11/10/2026)

Analytical breakdowns and data insights for company gtglabs.com (GENE)

- stock price and consensus target price:

Stock Quotes Genetic Technologies Limited|GENE - Average Forecast Price

- company stock capitalization data:

Market Value Genetic Technologies Limited|GENE - Company Buyout Price

- book value of equity indicators:

Book Value per Share Genetic Technologies|GENE - Book Valuation of Business|Market Value to Book Value Ratio gtglabs.com|GENE - Company Total Asset Base

- company liabilities and liquidity data:

Total Debt to Capital Genetic Technologies|GENE - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Genetic Technologies Limited|GENE - Company Cumulative Debt|Debt to Book Capitalization Ratio Genetic Technologies Limited|GENE - Company Long-Term Indebtedness|Company Short-Term Debts Genetic Technologies|Quick Liquidity Indicator gtglabs.com

- financial results and valuation multiples details:

GENE - Profit After Payment of Taxes|Projected Future Earnings Genetic Technologies|GENE - Business Payback Period|Forward P/E Multiple Genetic Technologies Limited|GENE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Genetic Technologies Limited|GENE - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Genetic Technologies|GENE - Earnings per share for the last four quarters|Quarterly EPS earnings growth gtglabs.com|GENE - Earnings per share growth rate in current year|Earnings growth forecast for next year Genetic Technologies

Initial company analysis:GENE (GTG Labs)

The EV/EBITDA multiple determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest. This calculation allows for an assessment of the asset's real value by excluding the impact of debt load and accounting policies. By analyzing the enterprise value to EBITDA ratio of Genetic Technologies (GENE), an investor can evaluate the capital intensity of Genetic Technologies (GENE) in developing predictive genetic tests for early oncology diagnostics.

Competitor analysis for Genetic Technologies

Agilent Tech - Enterprise Value to EBITDA Ratio|Quest Corp (DGX) - Company Value to EBITDA|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|RVTY: EV/EBITDA Multiple|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple QDEL|opko.com (OPK) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CDNA (CareDx Inc)|Maravai LifeSciences Holdings (MRVI) - Company Value to EBITDA|FLGT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAB (Standard BioTools Corp) - Enterprise Value to Operating Income Before Depreciation|CTKB: EV/EBITDA Multiple|Company Value to EBITDA orasure.com (OSUR)|Enterprise Value to EBITDA Ratio XGN|MDXH (MDxHealth S.A.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LUCD|Total Company Value to Operating Income Before Depreciation Ratio prenetics.com|EV/EBITDA Multiple IMDX (Insight Molecular Diagnostics Inc)|TRIB - Enterprise Value to EBITDA Ratio|PRPH: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AIMD (Ainos Inc)|CODX (Co-Diagnostics Corp) - Enterprise Value to EBITDA Ratio|HSCS: Enterprise Value to Operating Income Before Depreciation Ratio|BMRA (Biomerica, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Cardio Diagnostics Holdings, Inc. CDIO|EV/EBITDA Multiple ONCO|Enterprise Value to EBITDA Ratio Virax Biolabs Group Limited VRAX|EV/EBITDA Multiple BJDX (Bluejay)|Business Value to Operating Income Before Depreciation AWH|AXDX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CNTG (Centogene) - Enterprise Value to Operating Income Before Depreciation|enzo.com (ENZ) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Fresh2 Group (FRES)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PMD